Avanafil’s Efficacy and Pharmacokinetics in Hypertensive American Males: A Cohort Study
Reading Time: 2 minutes Introduction The management of erectile dysfunction (ED) in patients with comorbidities such as hypertension presents unique challenges due to potential drug interactions and altered pharmacokinetics. Stendra (avanafil), a phosphodiesterase type 5 (PDE5) inhibitor, has emerged as a promising treatment for ED due to its rapid onset and short duration of action. This article delves into a detailed cohort study focused on American males with hypertension, examining the pharmacokinetics of avanafil, its interactions with common antihypertensive medications, and its overall efficacy in this specific population. Study Design and Methodology Our cohort study included 250 American males aged between 45 and 70...


